As every year, during the EASL Congress, ELPA convened its Annual General Meeting. On June 21, 2023, ELPA members all gathered for this special occasion, voted on the Annual and Financial Reports 2022 but also had the possibility to share good practices and talk about the work done so far.
On the same day, in the afternoon, ELPA organised Educational Training for its members. Representatives from Mirum Pharma, Cellaion, and CymaBay presented the update from their companies in the field of rare liver diseases, PBC and a broad spectrum of liver diseases, from life-threatening acute-on-chronic liver failure (ACLF) and acute alcoholic hepatitis (AAH) to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH).
The rest of the days, a group of 9 ELPA member representatives enrolled in the new edition of the ELPA Clinical Trials Programme – Building patients’ experts in NASH clinical trials. They had the possibility to listen to presentations about:
- Why should I participate in a NASH clinical trial?
- Overview research & development.
- Process of medicine discovery and development.
- Concepts of evidence-based medicines and outcomes research.
- Predisposing factors and underlying mechanisms of disease.
- Types of medicines and their mode of action and use.
- Role of patients and patient organisations in NASH clinical trials.
- Understanding preclinical drug development.